Skip to main content

Table 1 Patient characteristics

From: Clinical features and outcomes of germline mutation BRCA1-linked versus sporadic ovarian cancer patients

Number of patients n = 125
Median (range) age at diagnosis in years 55 (28–85)
Performance status WHO:
 ▪ 0 15.2 % (19/125)
 ▪ 1 77.6 % (97/125)
 ▪ 2 7.2 % (9/125)
BSA (m2) 1.69 (95 % CI; 1.65–1.72)
FIGO stage:
 ▪ I 11.2 % (14/125)
 ▪ II 8.0 % (10/125)
 ▪ IIIA 5.6 % (7/125)
 ▪ IIIB 7.2 % (9/125)
 ▪ IIIC 56.0 % (70/125)
 ▪ IV 12.0 % (15/125)
Chemotherapy regimen:
 ▪ Paclitaxel/cisplatin 43.2 % (54/125)
 ▪ Paclitaxel/carboplatin/ caelyx 8.8 % (11/125)
 ▪ Paclitaxel/carboplatin 36.8 % (46/125)
 ▪ Carboplatin 8.8 % (11/125)
 ▪ Paclitaxel/carboplatin/epirubicin 1.6 % (2/125)
 ▪ Gemcitabine/ cisplatin 0.8 % (1/125)
Type of histology:
 ▪ Serous 54.4 % (68/125)
 ▪ Endometrioid 26.4 %(33/125)
 ▪ Mucinous 7.2 % (9/125)
 ▪ Clear cell 4.0 % (5/125)
 ▪ Mixed 2.4 % (3/125)
 ▪ Unspecified 5.6 % (7/125)
Grading:
 ▪ 1 3.2 % (4/125)
 ▪ 2 32.8 % (41/125)
 ▪ 3 23.2 % (29/125)
 ▪ Unspecified 40.8 % (51/125)
Primary surgery:
 ▪ Radical 19.2 % (24/125)
 ▪ Optimal (<1 cm) 42.4 % (53/125)
 ▪ Suboptimal (>1 cm) 38.4 % (48/125)